Abstract
American Journal of HematologyVolume 77, Issue 4 p. 420-420 Letters and CorrespondenceFree Access Reciprocal Relationship Between a Ph-Negative Clone With Trisomy 8 Associated With Severe Myelodysplasia and a Ph-Positive Clone Following Imatinib Treatment in a Patient With Accelerated-Phase Chronic Myelogenous Leukemia (CML) Paulina Patchenko, Paulina Patchenko Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this authorAbraham Klepfish, Abraham Klepfish Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this authorLuba Trakhtenbrot, Luba Trakhtenbrot Institute of Hematology, Sheba Medical Center, Tel-Hashomer, IsraelSearch for more papers by this authorRachel Rothman, Rachel Rothman Institute of Hematology, Sheba Medical Center, Tel-Hashomer, IsraelSearch for more papers by this authorEliezer A Rachmilewitz, Eliezer A Rachmilewitz Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this author Paulina Patchenko, Paulina Patchenko Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this authorAbraham Klepfish, Abraham Klepfish Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this authorLuba Trakhtenbrot, Luba Trakhtenbrot Institute of Hematology, Sheba Medical Center, Tel-Hashomer, IsraelSearch for more papers by this authorRachel Rothman, Rachel Rothman Institute of Hematology, Sheba Medical Center, Tel-Hashomer, IsraelSearch for more papers by this authorEliezer A Rachmilewitz, Eliezer A Rachmilewitz Institute of Hematology, E. Wolfson Medical Center, Holon, IsraelSearch for more papers by this author First published: 22 November 2004 https://doi.org/10.1002/ajh.20226Citations: 6AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat REFERENCES 1O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994– 1004. 2Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients; 14 months' experience. Blood 2002; 100: 435– 441. 3Bumm T, Müller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph− cells in some CML patients in cytogenetic remission to imatinib restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941– 1949. 4Royer-Pokora B, Hildebrandt B, Redmann A, et al. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia 2003; 17: 807– 810. 5Andersen MK. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Spotlight correspondence. Leukemia 2002; 16: 1390– 1395. Citing Literature Volume77, Issue4December 2004Pages 420-420 ReferencesRelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
